Gabriel Silva

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes

L. Been, D. Angiolillo, F. Franchi, 2020, JACC. Basic to translational science.

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus

L. Been, V. Kairouz, D. Angiolillo, 2019, JACC. Basic to translational science.

P1930Pharmacodynamic effects of vorapaxar as an add-on antiplatelet therapy in patients with and without diabetes mellitus: the optimizing anti-platelet therapy in diabetes mellitus (OPTIMUS)-5 study

V. Kairouz, D. Angiolillo, F. Franchi, 2019, European Heart Journal.

Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study

L. Been, R. Mehran, U. Baber, 2020, Journal of the American Heart Association.

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of the CANTIC Study

L. Been, D. Angiolillo, F. Franchi, 2019, Circulation.

Abstract 12535: Adjunctive Vorapaxar Therapy in Patients With Prior Myocardial Infarction Treated With Newer Generation P2y12 Receptor Inhibitors Prasugrel and Ticagrelor (VORA-PRATIC): A Prospective, Randomized, Pharmacodynamic Study

L. Been, D. Angiolillo, F. Rollini, 2019 .